• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX
Click for more information
1.01% 10.0¢

NOXOPHARM LIMITED - Announcements

Market Cap $29.22M  ! watchlist Created with Sketch. Add to my watchlist

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
NOX Results of Meeting23/11/16
NOX Breakthrough in Delivering Idronoxil into BrainPRICE SENSITIVE23/11/16
NOX Corporate Presentation Updated22/11/16
NOX Corporate Presentation22/11/16
NOX Corporate Presentation Providing Clinical Program Guidance22/11/16
NOX Medical Advisors Appointed for Extensive Clinical Program17/11/16
NOX Change in substantial holding DH14/11/16
NOX Appendix 4C - quarterly-NOX.AX PRICE SENSITIVE31/10/16
NOX Initial Clinic Study Announced and Approved-NOX.AX PRICE SENSITIVE26/10/16
NOX Noxopharm 2016 AGM Sydney Briefing-NOX.AX 24/10/16
NOX Notice of 2016 AGM and 2016 Annual Report-NOX.AX 21/10/16
NOX Corporate Presentation-NOX.AX 20/10/16
NOX Annual Report to shareholders-NOX.AX 03/10/16
NOX Appendix 4G-NOX.AX 03/10/16
NOX Amendment to Preliminary Final Report-NOX.AX PRICE SENSITIVE30/09/16
NOX Corporate Presentation for Roadshow-NOX.AX 12/09/16
NOX Preliminary Final Report-NOX.AX PRICE SENSITIVE31/08/16
NOX Change in substantial holding-NOX.AX 28/08/16
NOX Change in substantial holding-NOX.AX 25/08/16
NOX Change in substantial holding DH-NOX.AX 22/08/16
NOX Noxopharm to Initiate Radiotherapy Clinical Studies-NOX.AX PRICE SENSITIVE22/08/16
NOX Change of Director's Interest Notice - GK-NOX.AX 19/08/16
NOX Becoming a substantial holder-NOX.AX 10/08/16
NOX Becoming a substantial holder-NOX.AX 10/08/16
NOX Becoming a substantial holder-NOX.AX 10/08/16
NOX Initial Director's Interest Notice - PM-NOX.AX 10/08/16
NOX Initial Director's Interest Notice - ID-NOX.AX 10/08/16
NOX Initial Director's Interest Notice - GK-NOX.AX 10/08/16
NOX Noxopharm Provides Update on Inaugural Clinical Study-NOX.AX PRICE SENSITIVE10/08/16
NOX Noxopharm Limited commences trading on ASX-NOX.AX 09/08/16
NOX Performance Share Terms-NOX.AX 08/08/16
NOX Option Terms-NOX.AX 08/08/16
NOX Restricted Securities and Capital Structure-NOX.AX 08/08/16
NOX Securities Trading Policy-NOX.AX 08/08/16
NOX Financial Accounts-NOX.AX 08/08/16
NOX Constitution-NOX.AX 08/08/16
NOX ASX Market Release - Admission to Official List-NOX.AX PRICE SENSITIVE08/08/16
NOX Appendix 1A & Information Form and Checklist-NOX.AX 08/08/16
NOX Top 20 Holders-NOX.AX 08/08/16
NOX Distribution Schedule-NOX.AX 08/08/16
NOX Company's Admission Disclosures-NOX.AX 08/08/16
NOX ASX Market Release - Pre-Quotation Disclosure-NOX.AX 08/08/16
NOX ASX Market Release - Admission to Official List-NOX.AX PRICE SENSITIVE08/08/16
NOX Prospectus-NOX.AX 08/08/16
NOX ASX Notice - Admission and Commencement of Quotation-NOX.AX 08/08/16
NOX Results of Meeting
23/11/16
NOX Breakthrough in Delivering Idronoxil into Brain
23/11/16PRICE SENSITIVE
NOX Corporate Presentation Updated
22/11/16
NOX Corporate Presentation
22/11/16
NOX Corporate Presentation Providing Clinical Program Guidance
22/11/16
NOX Medical Advisors Appointed for Extensive Clinical Program
17/11/16
NOX Change in substantial holding DH
14/11/16
NOX Appendix 4C - quarterly-NOX.AX
31/10/16PRICE SENSITIVE
NOX Initial Clinic Study Announced and Approved-NOX.AX
26/10/16PRICE SENSITIVE
NOX Noxopharm 2016 AGM Sydney Briefing-NOX.AX
24/10/16
NOX Notice of 2016 AGM and 2016 Annual Report-NOX.AX
21/10/16
NOX Corporate Presentation-NOX.AX
20/10/16
NOX Annual Report to shareholders-NOX.AX
03/10/16
NOX Appendix 4G-NOX.AX
03/10/16
NOX Amendment to Preliminary Final Report-NOX.AX
30/09/16PRICE SENSITIVE
NOX Corporate Presentation for Roadshow-NOX.AX
12/09/16
NOX Preliminary Final Report-NOX.AX
31/08/16PRICE SENSITIVE
NOX Change in substantial holding-NOX.AX
28/08/16
NOX Change in substantial holding-NOX.AX
25/08/16
NOX Change in substantial holding DH-NOX.AX
22/08/16
NOX Noxopharm to Initiate Radiotherapy Clinical Studies-NOX.AX
22/08/16PRICE SENSITIVE
NOX Change of Director's Interest Notice - GK-NOX.AX
19/08/16
NOX Becoming a substantial holder-NOX.AX
10/08/16
NOX Becoming a substantial holder-NOX.AX
10/08/16
NOX Becoming a substantial holder-NOX.AX
10/08/16
NOX Initial Director's Interest Notice - PM-NOX.AX
10/08/16
NOX Initial Director's Interest Notice - ID-NOX.AX
10/08/16
NOX Initial Director's Interest Notice - GK-NOX.AX
10/08/16
NOX Noxopharm Provides Update on Inaugural Clinical Study-NOX.AX
10/08/16PRICE SENSITIVE
NOX Noxopharm Limited commences trading on ASX-NOX.AX
09/08/16
NOX Performance Share Terms-NOX.AX
08/08/16
NOX Option Terms-NOX.AX
08/08/16
NOX Restricted Securities and Capital Structure-NOX.AX
08/08/16
NOX Securities Trading Policy-NOX.AX
08/08/16
NOX Financial Accounts-NOX.AX
08/08/16
NOX Constitution-NOX.AX
08/08/16
NOX ASX Market Release - Admission to Official List-NOX.AX
08/08/16PRICE SENSITIVE
NOX Appendix 1A & Information Form and Checklist-NOX.AX
08/08/16
NOX Top 20 Holders-NOX.AX
08/08/16
NOX Distribution Schedule-NOX.AX
08/08/16
NOX Company's Admission Disclosures-NOX.AX
08/08/16
NOX ASX Market Release - Pre-Quotation Disclosure-NOX.AX
08/08/16
NOX ASX Market Release - Admission to Official List-NOX.AX
08/08/16PRICE SENSITIVE
NOX Prospectus-NOX.AX
08/08/16
NOX ASX Notice - Admission and Commencement of Quotation-NOX.AX
08/08/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.0¢ 		Change
0.001(1.01%) 		Mkt cap ! $29.22M
Open High Low Value Volume
10.0¢ 10.5¢ 10.0¢ $8.304K 80.52K

Buyers (Bids)

No. Vol. Price($)
2 124999 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 10000 1
View Market Depth
Last trade - 16.10pm 02/12/2024 (20 minute delay) ?
Last
10.5¢ 		  Change
0.001 ( 5.74 %)
Open High Low Volume
10.0¢ 10.5¢ 10.0¢ 149995
Last updated 14.08pm 02/12/2024 ?
NOX (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.